Results 141 to 150 of about 466,154 (153)

Moxifloxacin-induced QT interval prolongation and torsades de pointes: a narrative review

Expert Opinion on Drug Safety, 2018
Introduction: Moxifloxacin is widely used for the treatment of a number of infectious diseases because of its favorable pharmacological profile and high clinical success rate.
Fahadullah Khan, M. Ismail, Q. Khan, Zahid Ali   +3 more
semanticscholar   +1 more source

Validation and Clinical Utility of the hERG IC50:Cmax Ratio to Determine the Risk of Drug‐Induced Torsades de Pointes: A Meta‐Analysis

Pharmacotherapy, 2018
D. Lehmann, W. Eggleston, Dongliang Wang
semanticscholar   +1 more source

QT Prolongation, Torsades de Pointes, and Psychotropic Medications: A 5-Year Update.

Psychosomatics, 2017
S. Beach, C. Celano, A. Sugrue, C. Adams, M. Ackerman, P. Noseworthy, Jeff C. Huffman   +6 more
semanticscholar   +1 more source

Loperamide-Induced Torsades de Pointes: A Case Series.

Journal of Emergency Medicine, 2017
K. Katz, R. Cannon, M. Cook, A. Amaducci, Ryan Day, Joshua Enyart, Glenn A. Burket, Lauren M Porter, T. Roach, J. Janssen, Karl E. Williams   +10 more
semanticscholar   +1 more source

Mexiletine Prevents Recurrent Torsades de Pointes in Acquired Long QT Syndrome Refractory to Conventional Measures.

JACC Clinical Electrophysiology, 2015
Marwan Badri, Aashay Patel, Chinmay Patel, Gui-zhi Liu, M. Goldstein, Victoria M. Robinson, Xiaolin Xue, Lin Yang, P. Kowey, G. Yan   +9 more
semanticscholar   +1 more source

Torsades de Pointes Induced by the Concomitant Use of Ivabradine and Azithromycin: An Unexpected Dangerous Interaction

Cardiovascular Toxicology, 2014
G. Cocco, P. Jerie
semanticscholar   +1 more source

Citalopram, QTc Prolongation, and Torsades de Pointes.

Psychosomatics, 2015
R. Tampi, Michael Balderas, Kathleen V. Carter, Deena Tampi, M. Moca, A. Knudsen, Jacquelyn May   +6 more
semanticscholar   +1 more source